Advanced in Nontuberculous Mycobacterial Lung Disease

Dr. Ronald G. Nahass

Infectious Disease
105 Raider Blvd, Suite 101, 
Hillsborough, NJ 
On Staff At
Accepting New Patients
Offers Telehealth
38 Years of Experience
Advanced in Nontuberculous Mycobacterial Lung Disease
105 Raider Blvd, Suite 101, 
Hillsborough, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ronald Nahass is an Infectious Disease provider in Hillsborough, New Jersey. Dr. Nahass has been practicing medicine for over 38 years and is rated as an Advanced provider by MediFind in the treatment of Nontuberculous Mycobacterial Lung Disease. His top areas of expertise are Hepatitis C, Hepatitis, Hepatitis B, and Lyme Disease. Dr. Nahass is currently accepting new patients.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Medicine And Dentistry Of New Jersey
Residency
University Hospital - UMDNJ
Specialties
Infectious Disease
Licenses
Internal Medicine in NJ
Board Certifications
Infectious Disease, 1988
Internal Medicine, 1985
Fellowships
Robert Wood Johnson University Hospital
Hospital Affiliations
Robert Wood Johnson University Hospital - Somerset
University Medical Center Of Princeton At Plainsboro
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

ID Care, Hillsborough
105 Raider Blvd, Suite 101, Hillsborough, NJ 08844
Other Locations
ID Care, Somerset
49 Veronica Avenue, Suite 102, Somerset, NJ 08873
ID Care, Princeton
10 Forrestal Road South, Suite 203, Princeton, NJ 08540

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection
A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drugs: AB-729, Peg-IFN?-2a
Study Phase: Phase 2
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Current antiretroviral regimen
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

46 Total Publications

Genetic and Inflammatory Signatures Associated With Worse Prognosis in Hospitalized Patients With Severe SARS-CoV-2 Infection With and Without Diabetes.
Genetic and Inflammatory Signatures Associated With Worse Prognosis in Hospitalized Patients With Severe SARS-CoV-2 Infection With and Without Diabetes.
Journal: Journal of medical virology
Published: October 12, 2024
Similar Doctors
Distinguished in Nontuberculous Mycobacterial Lung Disease
Dr. Keith W. Hamilton
Infectious Disease
Distinguished in Nontuberculous Mycobacterial Lung Disease
Dr. Keith W. Hamilton
Infectious Disease

MacGregor Infection Medicine And Travel Program

3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
 (51.8 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Keith Hamilton is an Infectious Disease provider in Philadelphia, Pennsylvania. Dr. Hamilton is rated as an Advanced provider by MediFind in the treatment of Nontuberculous Mycobacterial Lung Disease. His top areas of expertise are Nontuberculous Mycobacterial Lung Disease, Sepsis, Leprosy, and Swimming Pool Granuloma. Dr. Hamilton is currently accepting new patients.

Distinguished in Nontuberculous Mycobacterial Lung Disease
Dr. Christopher L. Vinnard
Infectious Disease
Distinguished in Nontuberculous Mycobacterial Lung Disease
Dr. Christopher L. Vinnard
Infectious Disease

University Physician Associates Of New Jersey Inc

140 Bergen St, 
Newark, NJ 
 (24.3 miles away)
973-972-9000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Christopher Vinnard is an Infectious Disease provider in Newark, New Jersey. Dr. Vinnard is rated as a Distinguished provider by MediFind in the treatment of Nontuberculous Mycobacterial Lung Disease. His top areas of expertise are Tuberculous Meningitis, Nontuberculous Mycobacterial Lung Disease, Bacterial Meningitis, and Meningitis. Dr. Vinnard is currently accepting new patients.

Sarah Taimur
Distinguished in Nontuberculous Mycobacterial Lung Disease
Dr. Sarah Taimur
Infectious Disease
Distinguished in Nontuberculous Mycobacterial Lung Disease
Dr. Sarah Taimur
Infectious Disease

Icahn School Of Medicine At Mount Sinai

10 E 102nd St, 
New York, NY 
 (36.0 miles away)
212-241-9410
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sarah Taimur is an Infectious Disease provider in New York, New York. Dr. Taimur is rated as an Advanced provider by MediFind in the treatment of Nontuberculous Mycobacterial Lung Disease. Her top areas of expertise are Nontuberculous Mycobacterial Lung Disease, Strongyloidiasis, Cytomegalovirus Infection, and Cytomegalic Inclusion Disease.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nahass's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile